 |
|
|
| |
TD-6450, a Heterodimeric HCV NS5A Inhibitor with a High Barrier to Resistance and Pan-Genotypic Potency
|
| |
| |
Reported by Jules Levin
HEP DART 2013:
Frontiers in Drug Development for Viral Hepatitis.
December 8-12, 2013 · Big Island, Hawaii, USA.
J Budman, CE Waltman, W Krey-Epstein, R Chang, S Smith, A Amrite, M Mammen, M McKinnell Theravance, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
